These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 23222898)
1. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients. Schober T; Framke T; Kreipe H; Schulz TF; Großhennig A; Hussein K; Baumann U; Pape L; Schubert S; Wingen AM; Jack T; Koch A; Klein C; Maecker-Kolhoff B Transplantation; 2013 Jan; 95(1):240-6. PubMed ID: 23222898 [TBL] [Abstract][Full Text] [Related]
2. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia. Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618 [TBL] [Abstract][Full Text] [Related]
3. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan. Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698 [TBL] [Abstract][Full Text] [Related]
4. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103 [TBL] [Abstract][Full Text] [Related]
5. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience. Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652 [TBL] [Abstract][Full Text] [Related]
13. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Karuturi M; Shah N; Frank D; Fasan O; Reshef R; Ahya VN; Bromberg M; Faust T; Goral S; Schuster SJ; Stadtmauer EA; Tsai DE Transpl Int; 2013 Jun; 26(6):616-22. PubMed ID: 23551167 [TBL] [Abstract][Full Text] [Related]
15. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes. Berglund D; Kinch A; Edman E; Backlin C; Enblad G; Larsson E; Molin D; Pauksens K; Sundström C; Baecklund E Transplantation; 2015 May; 99(5):1036-42. PubMed ID: 25211518 [TBL] [Abstract][Full Text] [Related]
16. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients. Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous lymphoproliferative disorders in organ transplant recipients: update 2014. Seçkin D G Ital Dermatol Venereol; 2014 Aug; 149(4):401-8. PubMed ID: 25068227 [TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder: no relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients. Longmore DK; Conwell LS; Burke JR; McDonald SP; McTaggart SJ Pediatr Transplant; 2013 Dec; 17(8):731-6. PubMed ID: 24164826 [TBL] [Abstract][Full Text] [Related]
19. Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria. Füreder A; Kropshofer G; Benesch M; Dworzak M; Greil S; Huber WD; Hubmann H; Lawitschka A; Mann G; Michel-Behnke I; Müller-Sacherer T; Pichler H; Simonitsch-Klupp I; Schwinger W; Szepfalusi Z; Crazzolara R; Attarbaschi A; Cancer Rep (Hoboken); 2021 Oct; 4(5):e1375. PubMed ID: 33755341 [TBL] [Abstract][Full Text] [Related]